

Jemperli (dostarlimab-gxly) - Updated indication

- On February 10, 2023, <u>GSK announced</u> that the <u>FDA granted</u> <u>full approval</u> to <u>Jemperli</u> (<u>dostarlimab-gxly</u>), for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
 - Jemperli previously received accelerated approval for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer that had progressed on or following prior treatment with a platinum-containing regimen.
- Jemperli is also approved for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
 - This indication remains an accelerated approval.
- The full approval for Jemperli is based on additional data collected from the A1 expansion cohort
 of the ongoing GARNET trial, a phase 1, open-label, single-arm study in 141 patients with dMMR
 advanced or recurrent endometrial cancer that has progressed on or following prior treatment with
 a platinum-containing regimen. The major outcome measures were overall response rate (ORR)
 and duration of response (DOR).
 - The ORR was 45.4% (95% CI: 37.0, 54.0).
 - The median DOR was not reached (range: 1.2+, 52.8+ months).
- The recommended dosage of Jemperli is:
 - Dose 1 through dose 4: 500 mg every 3 weeks
 - Subsequent dosing beginning 3 weeks after dose 4 (dose 5 onwards): 1,000 mg every 6 weeks
 - Jemperli is administered as an intravenous infusion over 30 minutes. Patients are treated until disease progression or unacceptable toxicity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.